Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer

Medical Oncology

Volumn 31, Issue 4, 2014, Pages

  Şendur, Mehmet Ali Nahit ^a   Uncu, Dogan ^a   Zengin, Nurullah ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LAPATINIB; NAVELBINE; PACLITAXEL; TRASTUZUMAB; DEOXYCYTIDINE; DRUG DERIVATIVE; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ADULT; BRAIN METASTASIS; BREAST CARCINOMA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; FEMALE; HEADACHE; HISTOPATHOLOGY; HUMAN; LETTER; LIVER METASTASIS; LYMPH NODE DISSECTION; MAMMOGRAPHY; MASTECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; BRAIN TUMOR; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84893812499     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0890-y     Document Type: Letter

References (11)

1. Dawood S, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28(1):92-8.
2. Wolff AC, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-45.
3. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
4. Marty M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265-74.
5. Konecny GE, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630-9.
6. Geyer CE, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43.
7. Kimberly L. Blackwell, D.M., Luca Gianni, Ian E. Krop, Manfred Welslau, José Baselga, Mark D. Pegram, Do-Youn Oh, Veronique Dieras, Steven R. Olsen, Liang Fang, Michael W. Lu, Ellie Guardino, Sunil Verma. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 30. 2012(Suppl; abstr LBA1). 2012 ASCO Annual Meeting.
8. Lin NU, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-9.
9. Lin NU, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol. 2011;105(3):613-20.
10. Metro G, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol. 2011;22(3):625-30.
11. Bachelot T, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64-71.